These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30094815)

  • 1. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
    Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
    DeLoughery EP; Prasad V
    Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
    Wallach JD; Ciani O; Pease AM; Gonsalves GS; Krumholz HM; Taylor RS; Ross JS
    BMC Med; 2018 Mar; 16(1):45. PubMed ID: 29562926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 5. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
    Knopf K; Baum M; Shimp WS; Bennett CL; Faith D; Fishman ML; Hrushesky WJ
    BMJ; 2016 Dec; 355():i6286. PubMed ID: 28039123
    [No Abstract]   [Full Text] [Related]  

  • 6. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.
    Hudgins JD; Bacho MA; Olsen KL; Bourgeois FT
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):161-167. PubMed ID: 29148107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers and surrogate markers: an FDA perspective.
    Katz R
    NeuroRx; 2004 Apr; 1(2):189-95. PubMed ID: 15717019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
    Gyawali B; Kesselheim AS
    Nat Rev Clin Oncol; 2021 Jul; 18(7):397-398. PubMed ID: 33767454
    [No Abstract]   [Full Text] [Related]  

  • 11. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
    Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
    Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
    [No Abstract]   [Full Text] [Related]  

  • 12. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
    Leighton JK; Saber H; Reaman G; Pazdur R
    Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
    [No Abstract]   [Full Text] [Related]  

  • 13. Adaptive enrichment designs for confirmatory trials.
    Lai TL; Lavori PW; Tsang KW
    Stat Med; 2019 Feb; 38(4):613-624. PubMed ID: 30277591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA validation of surrogate endpoints in oncology: 2005-2022.
    Walia A; Haslam A; Prasad V
    J Cancer Policy; 2022 Dec; 34():100364. PubMed ID: 36155118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming the Activation of Clinical Trials.
    Watters JT; Pitzen JH; Sanders LJ; Bruce VNM; Cornell AR; Cseko GC; Grace JS; Kwon PS; Kukla AK; Lee MS; Monosmith MD; Myren JD; Kottschade RS; Shaft MN; Weis JJA; Welter JC; Bharucha AE
    Clin Pharmacol Ther; 2018 Jan; 103(1):43-46. PubMed ID: 29105757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and opportunities in bringing new medications to market for pediatric patients.
    Upadhyaya HP; Gault L; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
    [No Abstract]   [Full Text] [Related]  

  • 17. Oncology drug development: United States Food and Drug Administration perspective.
    Hirschfeld S; Pazdur R
    Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration.
    Green DJ; Liu XI; Hua T; Burnham JM; Schuck R; Pacanowski M; Yao L; McCune SK; Burckart GJ; Zineh I
    Clin Pharmacol Ther; 2018 Nov; 104(5):983-988. PubMed ID: 29218740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.